Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XERS Xeris Pharmaceuticals Inc

Trading 01-26 15:47:44 EST

7.48

+0.04

+0.59%

High7.58	Low7.36	Vol799.59K
Open7.40	D1 Closing7.44	Amplitude2.96%
Mkt Cap1.24B	Tradable Cap1.19B	Total Shares165.92M
T/O5.95M	T/O Rate0.50%	Tradable Shares159.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris Pharmaceuticals Inc","latestPrice":7.4841,"timestamp":1769460461025,"preClose":7.44,"halted":0,"volume":799586,"delay":0,"changeRate":0.0059274193548386235,"floatShares":159000000,"shares":165924289,"eps":-0.10439,"marketStatus":"Trading","change":0.0441,"latestTime":"01-26 15:47:44 EST","open":7.4,"high":7.5799,"low":7.36,"amount":5947374.240262,"amplitude":0.029556,"askPrice":7.49,"askSize":1113,"bidPrice":7.48,"bidSize":1723,"shortable":3,"etf":0,"ttmEps":-0.10439,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1769461200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":7.44,"preHourTrading":{"tag":"盘前","latestPrice":7.47,"preClose":7.44,"latestTime":"09:25 EST","volume":1224,"amount":9138.9169296,"timestamp":1769437500057,"change":0.03,"changeRate":0.004032,"amplitude":0.013401},"postHourTrading":{"tag":"盘后","latestPrice":7.59,"preClose":7.44,"latestTime":"18:29 EST","volume":383834,"amount":2855781.4651,"timestamp":1769210988101,"change":0.15,"changeRate":0.020161,"amplitude":0.020161},"volumeRatio":0.513064,"impliedVol":0.7815,"impliedVolPercentile":0.3347},"requestUrl":"/m/hq/s/XERS/tweets","defaultTab":"tweets","newsList":[{"id":"2604973146","title":"A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Updated 2025 Revenue Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2604973146","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604973146?lang=en_us&edition=fundamental","pubTime":"2026-01-18 16:18","pubTimestamp":1768724330,"startTime":"0","endTime":"0","summary":"Updated guidance puts Xeris Biopharma Holdings (XERS) on investors’ radar\nXeris Biopharma Holdings (XERS) lifted its full-year 2025 revenue outlook, now guiding to approximately US$292 million, above the prior US$285 million to US$290 million range. This is a shift that directly affects how investors may view the stock.\nSee our latest analysis for Xeris Biopharma Holdings.\nThe updated revenue outlook arrives after a mixed price run, with a 1-day share price return of 1.48% and a 90-day share...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/a-look-at-xeris-biopharma-holdings-xers-valuation-after-its","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/a-look-at-xeris-biopharma-holdings-xers-valuation-after-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XERS"],"gpt_icon":0},{"id":"2602304008","title":"Xeris Biopharma President and COO Kevin McCulloch Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602304008","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602304008?lang=en_us&edition=fundamental","pubTime":"2026-01-10 06:35","pubTimestamp":1767998134,"startTime":"0","endTime":"0","summary":"Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL7vJS7n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Xeris Biopharma President and COO Kevin McCulloch Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2602350379","title":"Xeris Biopharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2602350379","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602350379?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:37","pubTimestamp":1767965820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XERS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 08:37 ET (13:37 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2601366474","title":"Xeris Biopharma Expects 2025 Revenue to Reach $292 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366474","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366474?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:01","pubTimestamp":1767873699,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings Inc. has announced its financial outlook for 2025, expecting to deliver record total revenue of $292 million for the full year. This figure exceeds the previously guided range of $285-$290 million and represents a 44% increase compared to the prior year. The company also anticipates fourth quarter and full-year 2025 net revenue for Recorlev to reach $45 million and $139 million, respectively. Full-year 2025 financial results and the 2026 outlook are scheduled to be released on March 2, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via Business Wire  on January 08, 2026, and is solely responsible for the informat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDLbt5dyY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2601836615","title":"Xeris Biopharma Holdings Inc - Expects 2025 Revenue of $292 Mln, Exceeding Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2601836615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601836615?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA9RPLXP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2601536614","title":"Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2601536614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601536614?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA9RPLXP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2601849881","title":"Xeris Biopharma Holdings Inc. Officer John Patrick Shannon Jr. Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601849881","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601849881?lang=en_us&edition=fundamental","pubTime":"2026-01-07 07:15","pubTimestamp":1767741310,"startTime":"0","endTime":"0","summary":"John Patrick Shannon Jr., a Director and Officer of Xeris Biopharma Holdings Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDLXW4XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma Holdings Inc. Officer John Patrick Shannon Jr. Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2601853952","title":"Xeris Biopharma Officer Beth Hecht Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601853952","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601853952?lang=en_us&edition=fundamental","pubTime":"2026-01-06 07:02","pubTimestamp":1767654150,"startTime":"0","endTime":"0","summary":"Beth Hecht, an officer of Xeris Biopharma Holdings Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL9wnc9k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma Officer Beth Hecht Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2600093096","title":"BRIEF-Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2600093096","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600093096?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:07","pubTimestamp":1767391670,"startTime":"0","endTime":"0","summary":"BRIEF-Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Jan 2 (Reuters) - Xeris Biopharma Holdings Inc XERS.O:XERIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nTUA89Z2PG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2600980710","title":"Xeris Biopharma Grants 181,550 Restricted Stock Units to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2600980710","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600980710?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:15","pubTimestamp":1767388508,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings Inc. has granted restricted stock units representing a total of 181,550 shares of its common stock to 50 new employees under its Inducement Equity Plan. The restricted stock units will vest over three years in equal annual installments, contingent upon continued employment with the company or its subsidiaries.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via Business Wire  on January 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL6TqQkS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2593048275","title":"Have Xeris Biopharma Holdings Insiders Been Selling Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593048275","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593048275?lang=en_us&edition=fundamental","pubTime":"2025-12-22 18:18","pubTimestamp":1766398703,"startTime":"0","endTime":"0","summary":"Some Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) shareholders may be a little concerned to see that the Independent...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/have-xeris-biopharma-holdings-insiders-been-selling-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/have-xeris-biopharma-holdings-insiders-been-selling-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2592186631","title":"Director John Johnson Reports Sale of Xeris Biopharma Holdings Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592186631","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592186631?lang=en_us&edition=fundamental","pubTime":"2025-12-20 06:18","pubTimestamp":1766182701,"startTime":"0","endTime":"0","summary":"John Johnson, Director, reported a disposal of common shares of Xeris Biopharma Holdings Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL7MYxy0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director John Johnson Reports Sale of Xeris Biopharma Holdings Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2591275376","title":"Director Barbara-Jean Anne Bormann-Kennedy Sells Xeris Biopharma Holdings Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591275376","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591275376?lang=en_us&edition=fundamental","pubTime":"2025-12-16 06:24","pubTimestamp":1765837494,"startTime":"0","endTime":"0","summary":"Barbara-Jean Anne Bormann-Kennedy, Director at Xeris Biopharma Holdings Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL7KYk9P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Barbara-Jean Anne Bormann-Kennedy Sells Xeris Biopharma Holdings Inc. Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2590328286","title":"Xeris Biopharma Initiated at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2590328286","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590328286?lang=en_us&edition=fundamental","pubTime":"2025-12-10 00:38","pubTimestamp":1765298280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XERS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 11:38 ET (16:38 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2590495203","title":"Barclays Initiates Xeris Biopharma Holdings at Overweight With $9 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2590495203","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590495203?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:06","pubTimestamp":1765285564,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings (XERS) has an average rating of buy and mean price target of $11.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2588061642","title":"Xeris Biopharma Officer Beth Hecht Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588061642","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588061642?lang=en_us&edition=fundamental","pubTime":"2025-12-03 06:14","pubTimestamp":1764713691,"startTime":"0","endTime":"0","summary":"Beth Hecht, an officer at Xeris Biopharma Holdings Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL6FZc7Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma Officer Beth Hecht Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2588722393","title":"Xeris Biopharma Holdings Inc - Unit Receives Uspto Notice of Allowance for XP-8121 Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722393?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:08","pubTimestamp":1764590908,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2588724036","title":"Xeris Biopharma Receives Notice of Allowance from USPTO for XP-8121 Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724036","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724036?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:01","pubTimestamp":1764590475,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for its patent application covering XP-8121, a novel product candidate. The allowed claims are specific to the XP-8121 formulation. The patent is expected to be issued following standard administrative steps. Xeris is also pursuing additional intellectual property protection related to levothyroxine technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via Business Wire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL5hLKSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2584926252","title":"Xeris Biopharma Q3 Net Income USD 621 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926252","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926252?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:52","pubTimestamp":1763571139,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Xeris Biopharma Q3 EPS USD 0.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202511:00:00.293 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD8RCXxK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2584670975","title":"Xeris Biopharma Holdings Inc. Director and Officer John Patrick Shannon Jr. Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584670975","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584670975?lang=en_us&edition=fundamental","pubTime":"2025-11-18 06:59","pubTimestamp":1763420371,"startTime":"0","endTime":"0","summary":"John Patrick Shannon Jr., Director and Officer at Xeris Biopharma Holdings Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL9t66vd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma Holdings Inc. Director and Officer John Patrick Shannon Jr. Reports Disposal of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":-0.0106},{"period":"1month","weight":0.0319},{"period":"3month","weight":-0.1922},{"period":"6month","weight":0.4821},{"period":"1year","weight":1.1818},{"period":"ytd","weight":-0.0522}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.068784},{"month":2,"riseRate":0.714286,"avgChangeRate":-0.011486},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.030403},{"month":4,"riseRate":0.428571,"avgChangeRate":0.030526},{"month":5,"riseRate":0.714286,"avgChangeRate":0.17169},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.067395},{"month":7,"riseRate":0.5,"avgChangeRate":-0.009808},{"month":8,"riseRate":0.625,"avgChangeRate":0.207997},{"month":9,"riseRate":0.375,"avgChangeRate":-0.064053},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004147},{"month":11,"riseRate":0.5,"avgChangeRate":-0.025098},{"month":12,"riseRate":0.625,"avgChangeRate":0.051713}],"exchange":"NASDAQ","name":"Xeris Pharmaceuticals Inc","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xeris Pharmaceuticals Inc,XERS,Xeris Pharmaceuticals Inc股票,Xeris Pharmaceuticals Inc股票老虎,Xeris Pharmaceuticals Inc股票老虎国际,Xeris Pharmaceuticals Inc行情,Xeris Pharmaceuticals Inc股票行情,Xeris Pharmaceuticals Inc股价,Xeris Pharmaceuticals Inc股市,Xeris Pharmaceuticals Inc股票价格,Xeris Pharmaceuticals Inc股票交易,Xeris Pharmaceuticals Inc股票购买,Xeris Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction